Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The Novel, Clinical-Stage Soluble Guanylate Cyclase Activator BI 685509 Protects from Disease Progression in Models of Renal Injury and Disease.
Reinhart GA, Harrison PC, Lincoln K, Chen H, Sun P, Hill J, Qian HS, McHugh MC, Clifford H, Ng KJ, Wang H, Fowler D, Gueneva-Boucheva K, Brenneman JB, Bosanac T, Wong D, Fryer RM, Sarko C, Boustany-Kari CM, Pullen SS. Reinhart GA, et al. Among authors: sarko c. J Pharmacol Exp Ther. 2023 Mar;384(3):382-392. doi: 10.1124/jpet.122.001423. Epub 2022 Dec 6. J Pharmacol Exp Ther. 2023. PMID: 36507845
A Soluble Guanylate Cyclase Activator Inhibits the Progression of Diabetic Nephropathy in the ZSF1 Rat.
Boustany-Kari CM, Harrison PC, Chen H, Lincoln KA, Qian HS, Clifford H, Wang H, Zhang X, Gueneva-Boucheva K, Bosanac T, Wong D, Fryer RM, Richman JG, Sarko C, Pullen SS. Boustany-Kari CM, et al. Among authors: sarko c. J Pharmacol Exp Ther. 2016 Mar;356(3):712-9. doi: 10.1124/jpet.115.230706. Epub 2016 Jan 4. J Pharmacol Exp Ther. 2016. PMID: 26729306
In vivo selective inhibition of TRPC6 by antagonist BI 749327 ameliorates fibrosis and dysfunction in cardiac and renal disease.
Lin BL, Matera D, Doerner JF, Zheng N, Del Camino D, Mishra S, Bian H, Zeveleva S, Zhen X, Blair NT, Chong JA, Hessler DP, Bedja D, Zhu G, Muller GK, Ranek MJ, Pantages L, McFarland M, Netherton MR, Berry A, Wong D, Rast G, Qian HS, Weldon SM, Kuo JJ, Sauer A, Sarko C, Moran MM, Kass DA, Pullen SS. Lin BL, et al. Among authors: sarko c. Proc Natl Acad Sci U S A. 2019 May 14;116(20):10156-10161. doi: 10.1073/pnas.1815354116. Epub 2019 Apr 26. Proc Natl Acad Sci U S A. 2019. PMID: 31028142 Free PMC article.
Discovery and optimization of p38 inhibitors via computer-assisted drug design.
Goldberg DR, Hao MH, Qian KC, Swinamer AD, Gao DA, Xiong Z, Sarko C, Berry A, Lord J, Magolda RL, Fadra T, Kroe RR, Kukulka A, Madwed JB, Martin L, Pargellis C, Skow D, Song JJ, Tan Z, Torcellini CA, Zimmitti CS, Yee NK, Moss N. Goldberg DR, et al. Among authors: sarko c. J Med Chem. 2007 Aug 23;50(17):4016-26. doi: 10.1021/jm070415w. Epub 2007 Jul 20. J Med Chem. 2007. PMID: 17658737
Discovery and design of benzimidazolone based inhibitors of p38 MAP kinase.
Hammach A, Barbosa A, Gaenzler FC, Fadra T, Goldberg D, Hao MH, Kroe RR, Liu P, Qian KC, Ralph M, Sarko C, Soleymanzadeh F, Moss N. Hammach A, et al. Among authors: sarko c. Bioorg Med Chem Lett. 2006 Dec 15;16(24):6316-20. doi: 10.1016/j.bmcl.2006.09.014. Epub 2006 Sep 28. Bioorg Med Chem Lett. 2006. PMID: 17010605
Indole RSK inhibitors. Part 1: discovery and initial SAR.
Boyer SJ, Burke J, Guo X, Kirrane TM, Snow RJ, Zhang Y, Sarko C, Soleymanzadeh L, Swinamer A, Westbrook J, Dicapua F, Padyana A, Cogan D, Gao A, Xiong Z, Madwed JB, Kashem M, Kugler S, O'Neill MM. Boyer SJ, et al. Among authors: sarko c. Bioorg Med Chem Lett. 2012 Jan 1;22(1):733-7. doi: 10.1016/j.bmcl.2011.10.030. Epub 2011 Oct 14. Bioorg Med Chem Lett. 2012. PMID: 22100312
A new class of 5-HT2B antagonists possesses favorable potency, selectivity, and rat pharmacokinetic properties.
Moss N, Choi Y, Cogan D, Flegg A, Kahrs A, Loke P, Meyn O, Nagaraja R, Napier S, Parker A, Thomas Peterson J, Ramsden P, Sarko C, Skow D, Tomlinson J, Tye H, Whitaker M. Moss N, et al. Among authors: sarko c. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2206-10. doi: 10.1016/j.bmcl.2009.02.126. Epub 2009 Mar 9. Bioorg Med Chem Lett. 2009. PMID: 19307114
Discovery and optimization of pyrazole amides as antagonists of CCR1.
Harcken C, Sarko C, Mao C, Lord J, Raudenbush B, Razavi H, Liu P, Swinamer A, Disalvo D, Lee T, Lin S, Kukulka A, Grbic H, Patel M, Patel M, Fletcher K, Joseph D, White D, Amodeo L, Berg K, Brown M, Thomson DS. Harcken C, et al. Among authors: sarko c. Bioorg Med Chem Lett. 2019 Feb 1;29(3):435-440. doi: 10.1016/j.bmcl.2018.11.015. Epub 2018 Nov 9. Bioorg Med Chem Lett. 2019. PMID: 30455146
Evolution of the thienopyridine class of inhibitors of IkappaB kinase-beta: part I: hit-to-lead strategies.
Morwick T, Berry A, Brickwood J, Cardozo M, Catron K, DeTuri M, Emeigh J, Homon C, Hrapchak M, Jacober S, Jakes S, Kaplita P, Kelly TA, Ksiazek J, Liuzzi M, Magolda R, Mao C, Marshall D, McNeil D, Prokopowicz A 3rd, Sarko C, Scouten E, Sledziona C, Sun S, Watrous J, Wu JP, Cywin CL. Morwick T, et al. Among authors: sarko c. J Med Chem. 2006 May 18;49(10):2898-908. doi: 10.1021/jm0510979. J Med Chem. 2006. PMID: 16686533
19 results